Lysyl oxidase propeptide stimulates osteoblast and osteoclast differentiation and enhances PC3 and DU145 prostate cancer cell effects on bone in vivo

Journal of Cell Communication and Signaling

Volumn 10, Issue 1, 2016, Pages 17-31

  Alsulaiman, Mona ^a   Bais, Manish V ^a   Trackman, Philip C ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

Bone; Differentiation; Lysyl oxidase; Lysyl oxidase propeptide; Osteoblast; Osteoclast

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; COLLAGEN TYPE 1; COLONY STIMULATING FACTOR 1; CONNECTIVE TISSUE GROWTH FACTOR; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROTEIN LYSINE 6 OXIDASE; RECOMBINANT LYSYL OXIDASE PROPEPTIDE; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BONE; BONE DESTRUCTION; BONE MARROW STROMA CELL; BONE STRUCTURE; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL FUSION; CELL PROLIFERATION; CONDITIONED MEDIUM; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; TIBIA; TUMOR GROWTH;

EID: 84949499960     PISSN: 18739601     EISSN: 1873961X     Source Type: Journal    
DOI: 10.1007/s12079-015-0311-9     Document Type: Article

References (39)

1. Agra N, Cidre F, Garcia-Garcia L, de la Parra J, Alonso J (2013) Lysyl oxidase is downregulated by the EWS/FLI1 oncoprotein and its propeptide domain displays tumor supressor activities in ewing sarcoma cells. PLoS ONE 8:e66281
2. Aoyama E, Kubota S, Khattab HM, Nishida T, Takigawa M (2015) CCN2 enhances RANKL-induced osteoclast differentiation via direct binding to RANK and OPG. Bone 73:242–248
3. Bais MV, Wigner N, Young M, Toholka R, Graves DT, Morgan EF, Gerstenfeld LC, Einhorn TA (2009) BMP2 is essential for post natal osteogenesis but not for recruitment of osteogenic stem cells. Bone 45:254–266
4. Bais MV, Nugent MA, Stephens DN, Sume SS, Kirsch KH, Sonenshein GE, Trackman PC (2012a) Recombinant lysyl oxidase propeptide protein inhibits growth and promotes apoptosis of pre-existing murine breast cancer xenografts. PLoS ONE 7:e31188
5. Bais MV, Shabin ZM, Young M, Einhorn TA, Kotton DN, Gerstnefeld LC (2012b) Role of nanog in the maintenance of marrow stromal stem cells during post natal bone regeneration. Biochem Biophys Res Commun 417:211–216
6. Bais MV, Ozdener GB, Sonenshein GE, Trackman PC (2015) Effects of tumor-suppressor lysyl oxidase propeptide on prostate cancer xenograft growth and its direct interactions with DNA repair pathways. Oncogene 34:1928–1937
7. Black Jr SA, Trackman PC (2008) Transforming growth factor-beta1 (TGFbeta1) stimulates connective tissue growth factor (CCN2/CTGF) expression in human gingival fibroblasts through a RhoA-independent, Rac1/Cdc42-dependent mechanism: statins with forskolin block TGFbeta1-induced CCN2/CTGF expression. J Biol Chem. 283:10835–10847
8. Cox TR, Rumney RM, Schoof EM, Perryman L, Hoye AM, Agrawal A, Bird D, Latif NA, Forrest H, Evans HR, et al. (2015) The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 522:106–110
9. Edgar CM, Chakravarthy V, Barnes G, Kakar S, Gerstenfeld LC, Einhorn TA (2007) Autogenous regulation of a network of bone morphogenetic proteins (BMPs) mediates the osteogenic differentiation in murine marrow stromal cells. Bone 40:1389–1398
10. Hong HH, Pischon N, Santana RB, Palamakumbura AH, Chase HB, Gantz D, Guo Y, Uzel MI, Ma D, Trackman PC (2004) A role for lysyl oxidase regulation in the control of normal collagen deposition in differentiating osteoblast cultures. J Cell Physiol 200:53–62
11. Jeay S, Pianetti S, Kagan HM, Sonenshein GE (2003) Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-kappa B. Mol Cell Biol 23:2251–2263
12. Kagan HM, Trackman PC (1991) Properties and function of lysyl oxidase. Am J Respir Cell Mol Biol 5:206–210
13. Kenyon K, Contente S, Trackman PC, Tang J, Kagan HM, Friedman RM (1991) Lysyl oxidase and rrg messenger RNA. Science 253:802
14. Kessler E, Takahara K, Biniaminov L, Brusel M, Greenspan DS (1996) Bone morphogenetic protein-1. The type I procollagen C-proteinase. Science 271:360–362
15. Knott L, Bailey AJ (1998) Collagen cross-links in mineralizing tissues: a review of their chemistry, function, and clinical relevance. Bone 22:181–187
16. Krishnan B, Smith TL, Dubey P, Zapadka ME, Torti FM, Willingham MC, Tallant EA, Gallagher PE (2013) Angiotensin-(1–7) attenuates metastatic prostate cancer and reduces osteoclastogenesis. Prostate 73:71–82
17. Lees S, Eyre DR, Barnard SM (1990) BAPN dose dependence of mature crosslinking in bone matrix collagen of rabbit compact bone: corresponding variation of sonic velocity and equatorial diffraction spacing. Connect Tissue Res 24:95–105
18. Min C, Kirsch KH, Zhao Y, Jeay S, Palamakumbura AH, Trackman PC, Sonenshein GE (2007) The tumor suppressor activity of the lysyl oxidase propeptide reverses the invasive phenotype of her-2/neu-driven breast cancer. Cancer Res 67:1105–1112
19. Min C, Yu Z, Kirsch KH, Zhao Y, Vora SR, Trackman PC, Spicer DB, Rosenberg L, Palmer JR, Sonenshein GE (2009) A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. Cancer Res 69:6685–6693
20. Min C, Zhao Y, Romagnoli M, Trackman PC, Sonenshein GE, Kirsch KH (2010) Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubicin-induced apoptosis. J Cell Biochem 111:1160–1168
21. Nishida T, Emura K, Kubota S, Lyons KM, Takigawa M (2011) CCN family 2/connective tissue growth factor (CCN2/CTGF) promotes osteoclastogenesis via induction of and interaction with dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res 26:351–363
22. Oxlund H, Barckman M, Ortoft G, Andreassen TT. Reduced concentrations of collagen cross-links are associated with reduced strength of bone. Bone. 1995;17:365 s-371 s.
23. Ozdener GB, Bais MV, Trackman PC (2015) Determination of cell uptake pathways for tumor inhibitor lysyl oxidase propeptide. Mol Oncol. doi:10.1016/j.molonc
24. Palamakumbura AH, Jeay S, Guo Y, Pischon N, Sommer P, Sonenshein GE, Trackman PC (2004) The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. J Biol Chem. 279:40593–40600
25. Palamakumbura AH, Vora SR, Nugent MA, Kirsch KH, Sonenshein GE, Trackman PC (2009) Lysyl oxidase propeptide inhibits prostate cancer cell growth by mechanisms that target FGF-2-cell binding and signaling. Oncogene 28:3390–3400
26. Panchenko MV, Stetler-Stevenson WG, Trubetskoy OV, Gacheru SN, Kagan HM (1996) Metalloproteinase activity secreted by fibrogenic cells in the processing of prolysyl oxidase. Potential role of procollagen C-proteinase. J Biol Chem 271:7113–7119
27. Pettit AR, Chang MK, Hume DA, Raggatt LJ (2008) Osteal macrophages: a new twist on coupling during bone dynamics. Bone 43:976–982
28. Sanchez-Morgan N, Kirsch KH, Trackman PC, Sonenshein GE (2011) The lysyl oxidase propeptide interacts with the receptor-type protein tyrosine phosphatase kappa and inhibits beta-catenin transcriptional activity in lung cancer cells. Mol Cell Biol 31:3286–3297
29. Sato S, Trackman PC, Maki JM, Myllyharju J, Kirsch KH, Sonenshein GE (2011) The ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells. Mol Cell Biol 31:2683–2695
30. Sato S, Zhao Y, Imai M, Simister PC, Feller SM, Trackman PC, Kirsch KH, Sonenshein GE (2013) Inhibition of CIN85-mediated invasion by a novel SH3 domain binding motif in the lysyl oxidase propeptide. PLoS ONE 8:e77288
31. Trackman PC, Bedell-Hogan D, Tang J, Kagan HM (1992) Post-translational glycosylation and proteolytic processing of a lysyl oxidase precursor. J Biol Chem. 267:8666–8671
32. Tran Van P, Vignery A, Baron R (1982) An electron-microscopic study of the bone-remodeling sequence in the rat. Cell Tissue Res 225:283–292
33. Uauy R, Olivares M, Gonzalez M (1998) Essentiality of copper in humans. Am J Clin Nutr 67:952S–959S
34. Uzel MI, Scott IC, Babakhanlou-Chase H, Palamakumbura AH, Pappano WN, Hong HH, Greenspan DS, Trackman PC (2001) Multiple bone morphogenetic protein 1-related mammalian metalloproteinases process pro-lysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures. J Biol Chem. 276:22537–22543
35. Vora SR, Palamakumbura AH, Mitsi M, Guo Y, Pischon N, Nugent MA, Trackman PC (2010a) Lysyl oxidase propeptide inhibits FGF-2-induced signaling and proliferation of osteoblasts. J Biol Chem. 285:7384–7393
36. Vora SR, Guo Y, Stephens DN, Salih E, Vu ED, Kirsch KH, Sonenshein GE, Trackman PC (2010b) Characterization of recombinant lysyl oxidase propeptide. Biochemistry 49:2962–2972
37. Wu M, Min C, Wang X, Yu Z, Kirsch KH, Trackman PC, Sonenshein GE (2007) Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. Cancer Res 67:6278–6285
38. Yu Z, Sato S, Trackman PC, Kirsch KH, Sonenshein GE (2012) Blimp1 activation by AP-1 in human lung cancer cells promotes a migratory phenotype and is inhibited by the lysyl oxidase propeptide. PLoS ONE 7:e33287
39. Zhao Y, Min C, Vora SR, Trackman PC, Sonenshein GE, Kirsch KH (2009) The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells. J Biol Chem. 284:1385–1393